Experts discuss ongoing challenges and emerging options for treating anemia in myelofibrosis
Anemia frequently accompanies myelofibrosis and can worsen fatigue and overall prognosis. Clinicians often struggle to manage this complication effectively.
In a recent discussion, Dr. Aaron Gerds and Dr. Anthony M. Hunter outlined the current hurdles, noting that few therapies directly target anemia in this disease and that treatment decisions are hampered by a lack of reliable biomarkers.
They also highlighted several emerging therapeutic concepts, including novel agents and combination approaches, while calling for clearer biomarker guidance to better match patients with appropriate treatments.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Evolving Strategies for Myelofibrosis-Associated Anemia Highlight Persistent Gaps in Biomarker Guidance”
read at onclive ↗
comments(0)
5-min edit window · permanent after that